• Clario accelerates your clinical trial from initiation to implementation. LEARN MORE →

Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario
  • Solutions
    • eCOA Digital Solutions
      • eCOA Digital Solutions
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • FlexImaging
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Cough and Lung Sounds
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Clinical Trial Management
      • Electronic Data Capture (EDC)
      • Eligibility Solution
      • Payments
      • Randomization and trial supply management
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials
      • Decentralized Trials
      • eConsent
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Respiratory Solutions
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Values & Culture
    • Security Governance
    • Corporate & Social Responsibility
    • Leadership
    • Scientific Expertise
    • Strategic Partnerships
    • Legal & Privacy
  • Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Articles Total metabolic tumor volume — A valuable new method of assessment of global response to therapy

Total metabolic tumor volume — A valuable new method of assessment of global response to therapy

John G Wolodzko, PhD, DABSNM, FACNM – Sr. Medical Physicist at Clario

Over the past few years, many papers have been published by groups investigating the utility of 18F-fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) for screening and therapy response assessment in various lymphoma subtypes.

Several of these studies have reported the value of total metabolic tumor volume (TMTV) as a negative or positive prognostic indicator, based on a TMTV above or below a predetermined threshold at baseline, or as an indicator of response according to a change in TMTV over a course of treatment. Different approaches have been investigated for segmenting lesions for volume measurement, including the setting of image thresholds at fixed percentages of lesion maximum standard uptake values (SUVmax), e.g., the 41% of SUVmax suggested by the European Association of Nuclear Medicine (EANM); absolute SUV, e.g. SUV>= 4.0 as advised by the PETRA group; or a multiple of a reference value such as 2.5 times the Liver SUVmean. Although more than one group has concluded that the selection of the most sensitive baseline TMTV cutoff for the purpose of prognostic determination appears to be disease-specific, there is consensus that most, if not all, of the approaches to threshold setting have similar prognostic or response results when the selected method is applied consistently. In addition, at least one group of researchers have reported that FDG-PET-based TMTV evaluations are superior to approaches such as measurements of anatomical size or bulk or qualitative PET assessments such as numerical scoring systems in terms of predicting treatment outcomes or demonstrating response to treatment. TMTV measurements can potentially aid in the selection of patients for appropriate therapies or may support the modification of drug doses for maximum effectiveness.

FDG-PET-based TMTV measurement brings useful, independent, and correlative information to the clinical drug evaluation process. Clario can customize the segmentation threshold settings to meet any special requirements based on disease type or sponsor request or provide measurements based on multiple approaches to segmentation for sponsor downstream evaluation if desired. Additional data, such as Total Lesion Glycolysis (TLG), Fragmentation, and Dissemination based on metabolic tumor volume and distribution of lesions can also be provided for prognostic/response evaluation and can be included in the data provided to the sponsor for a comprehensive demonstration of drug efficacy.

Written by

John Wolodzko headshot

John G Wolodzko, PhD, DABSNM, FACNM

Sr. Medical Physicist at Clario


References

1Cottereau A.-S., Hapdey S., Chartier L., Modzelewski R., Casasnovas O., Itti E., Tilly H., Vera P., Meignan M., Becker S. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma. J. Nucl. Med. 2016;58:276–281

2A. S. Cottereau, S. Becker, F. Broussais et al., “Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL),” Annals of Oncology, vol. 27, no. 4, pp. 719–724, 2016

3Burggraaff CN, Rahman F, Kaßner I, Pieplenbosch S, Barrington SF, Jauw YWS, et al. Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol Imaging Biol. 2020;22:1102–10

Speak to our science experts to discuss your next oncology study.

Talk to a specialist

Subscribe to our newsletter

Stay up to date with the latest insights and best practices by subscribing to our newsletter. You’ll receive notifications whenever we publish new webinar replays, blog posts and other downloadable resources.

Back to articles
Share
Twitter Facebook LinkedIn

Latest external publications

See all
Peer-Reviewed

Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET

Read
Trade Publication

Artificial Intelligence in Gastroenterology

Read
Peer-Reviewed

The E/e′ ratio: As “critical” as the left ventricular ejection fraction?

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • News
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below or send us an email.

Customer support

Questions regarding your clinical trial technology or need technical support? Our customer care teams are ready to help you.

Customer support

Media contact

If you would like to speak with one of our innovators or thought leaders, connect with our public relations team.

Email: [email protected]

Our Locations

View our locations

Thanks for your form. Our team will be in touch very soon.

  • © 2023 Clario

    • Legal and Privacy Terms
    • Security Governance
    • Cookie Policy
    • Impressum

Please enter your business email before proceeding to xTalks to complete registration.

×